Wellness & Lifestyle

3Analytics offers AI-driven platforms designed to enhance safety and compliance across the pharmaceutical, medical device, and vaccine industries. The platform utilizes cutting-edge artificial intelligence and machine learning, including Natural Language Processing, to develop transformative solutions for safety analytics. Key offerings include Signal Management, Bio-Med Literature analysis, and IMDRF RegIntel, which optimize compliance, streamline workflows, and provide actionable insights. 3Analytics aims to empower healthcare organizations to make data-driven decisions, offering tailored, future-ready solutions that blend innovation and expertise. Their unique ADR/AE Analytics Engine provides comprehensive safety analytics for diverse segments, ensuring unmatched regulatory compliance capabilities.

LifeX Ventures is a venture capital firm dedicated to investing in companies that are commercializing scientific breakthroughs for human and planetary longevity. The firm focuses on innovations in health, climate, and AI, aiming to accelerate the adoption of new technologies. LifeX Ventures partners with founders who are developing solutions in areas such as biological artificial intelligence, AI-powered imaging for surgeries, AI-powered ECG interpretation, and platforms for outsourced life sciences research. Their portfolio includes companies addressing cancer research, immune system analysis, home energy storage, and warehouse automation with robotics and AI. The team comprises PhD scientists, serial founders, and experienced investors, providing strategic support beyond just capital.

Meta-Flux is an AI-powered drug discovery platform designed to revolutionize pharmaceutical development. It utilizes advanced artificial intelligence and multi-omic data analysis to provide adaptive experimentation capabilities. The platform aims to significantly improve and accelerate the drug discovery process by assisting researchers in identifying potential drug candidates more efficiently. By integrating AI into various stages of drug development, Meta-Flux helps overcome traditional bottlenecks, leading to faster identification of promising compounds and a more streamlined path from research to clinical application. This innovative approach supports the pharmaceutical industry in bringing life-saving drugs to market quicker.

Revisto is an AI-powered platform designed to accelerate and streamline medical, legal, and regulatory (MLR) reviews for life sciences marketing materials. It helps pharmaceutical, Medtech, and digital agencies reduce time-to-market by cutting review cycles by up to 90%. The platform identifies drug-related content issues early, maintains high-quality standards, and ensures compliance, saving companies millions annually. Revisto offers specific and actionable recommendations by understanding a company's unique data and provides features like automatic claim substantiation, content development acceleration, and single-cycle MLR reviews. It includes specialized AI agents for MLR review, claims generation, and claims extraction.

Aignostics specializes in leveraging AI to turn complex biomedical data into actionable insights for biopharma companies. The platform offers a range of products and services, including Pathology Foundation Models and the Atlas H&E-TME application for comprehensive tumor microenvironment profiling. Aignostics also provides custom services for target and biomarker discovery, translational research, and digital diagnostics, supporting the entire drug development pipeline from early discovery to clinical applications. With proprietary access to multimodal data from over 30 million patients and a team of deep biomedical experts, Aignostics aims to improve patient outcomes through advanced machine learning capabilities and cutting-edge academic collaborations.

Lir Therapeutics is at the forefront of gene therapy, leveraging an AI-first approach to reprogram viral vectors. The company's core mission is to overcome key challenges in gene therapy, focusing on dose reduction, precision targeting, and immune evasion. By improving the efficiency of viral vectors, Lir aims to reduce toxicity risks and lower the cost of gene therapies. Their nAAVigator® platform is a holistic viral design engine trained on unique datasets, engineered to model viral vectors at all levels for simultaneous safety and efficacy. This platform integrates immunogenicity landscape models, physics-based structural models, functional protein models, and viral DNA foundation models. Lir operates an integrated lab-in-the-loop, generating high-throughput data to drive its AI models and design precise experiments for advanced viral vector engineering.

Hill Research offers an AI-powered platform, TriClick™, designed to accelerate and optimize clinical trials. It leverages multi-agent AI and automation to streamline data workflows, ensuring compliance and reducing operational costs. The platform provides solutions for AI-Powered Biostatistics, Project-Based Biostatistics, and Biostatistics Functional Service Provider (FSP) needs. Key features include automated validation, anonymization, and audit trails for regulatory readiness, AI-driven annotation for speed and consistency, and automated generation of TLFs (Tables, Listings, Figures) from Statistical Analysis Plans (SAP). Hill Research aims to deliver 100% CDISC-ready and reproducible outputs, significantly accelerating TLF generation and annotation processes.

Ankr Health offers AI-powered virtual employees, such as Mira (AI Medical Assistant) and Frank (AI Scheduler), specifically designed for medical practices. These AI employees aim to address common healthcare challenges like excessive patient calls, staffing shortages, and high operational costs. Mira handles patient calls and messages, integrates with EHRs for documentation, and supports clinicians during visits. Frank manages scheduling, cancellations, and rebooking appointments, operating in co-pilot or autonomous modes and adhering to complex rules like Epic Cadence. The platform emphasizes compliance, security (HIPAA, SOC2, cyber liability coverage), and seamless integration with existing EHR workflows to improve efficiency, patient satisfaction, and revenue for healthcare organizations.

Profiter is an innovative AI-powered software specifically designed for pharmaceutical logistics and warehouse management. It leverages artificial intelligence to adapt to the unique characteristics of each medication, providing measurable data for unprecedented warehouse performance. The platform assists users in predicting future demand, planning reordering processes, and designing effective warehouse strategies. By integrating AI into the supply chain, Profiter aims to optimize processes, reduce financial waste, minimize risks, and recover capital. It boasts significant improvements in process efficiency, a reduction in average inventory levels, and a drastic decrease in stockouts due to inefficient replenishment. Profiter supports decision-making with demand forecasting, offers real-time stock level monitoring, and provides accessible statistics for warehouse management.

IMO Health is a clinical data intelligence business that structures and operationalizes clinical data using a comprehensive knowledge graph, combining rich medical terminology, extensive domain knowledge, and artificial intelligence. It addresses challenges like inaccurate coding, data standardization, denials management, and risk adjustment. The platform is deeply embedded in the provider space, integrating with major EHRs like Epic, Oracle, and MEDITECH. IMO Health's AI-powered solutions are grounded in domain-specific knowledge and achieve high accuracy in medical coding, supported by a team of subject matter experts including physicians and NLP scientists. It also supports life sciences organizations in evidence generation and clinical research by normalizing and enriching real-world data.

Peptris Technologies is an AI-powered preclinical drug discovery company focused on enhancing efficiencies across the drug discovery and development cascade. Their proprietary AI platform integrates unsupervised learning and generative AI to design optimized molecules, significantly reducing the need for wet lab testing. The automated platform streamlines the process of designing potent, safe, selective, and biologically active drug candidates. Peptris has successfully used its platform to discover Novel Chemical Entities (NCE), repurpose approved drugs for new indications, and rescue molecules that have proven safe in clinical trials. The company operates virtually, focusing on AI-driven discovery while outsourcing wet lab work to CROs and biotech partners. Revenue is generated through licensing deals, milestone payments, and royalties, with partnerships spanning academia, biotech, and pharma companies.

SyntheticGestalt is a company dedicated to advancing civilization through automatic invention, specifically focusing on drug discovery automation. The platform utilizes artificial intelligence and synthetic biology to streamline the research and development process, aiming to mass-produce valuable discoveries. Their mission involves developing an automatic system to accelerate the identification and creation of new drugs, facilitating joint research efforts, and contributing to the broader life sciences industry. The company also focuses on enzyme discovery, indicating a comprehensive approach to biological innovation.

Fastfold AI is a collaborative platform designed for scientists and AI agents to work together on scientific discovery, particularly in biological research. It offers an Agents IDE for fast iteration and workflow setup, allowing users to create and manage agent configurations with skills, tools, and workspace files. The platform supports reproducible agent sessions with selectable CPU/GPU configurations and curated runtimes, enabling complex scientific workflows from exploration to execution. Fastfold also features a visual workflow editor for composing multi-step pipelines, managed infrastructure for handling compute resources, and automated logging for experiment tracking. It aims to accelerate drug discovery and therapeutic development by providing a unified environment for the entire discovery loop.

FDNA is a leading AI-powered platform specializing in image analysis for the early detection and management of developmental and genetic disorders. It serves healthcare professionals, parents, and pharmaceutical companies by providing decision support tools for diagnosis and care management. The platform leverages a comprehensive database of phenotypic information and multi-modal algorithms, including Deep Gestalt® for syndrome mapping and Gestalt Matcher™ for discovering new syndromes. FDNA's technology is used in over 10,000 medical centers worldwide, supporting the patient's journey from early signs to treatment plans and facilitating interoperability between healthcare providers, patients, and the pharmaceutical industry.

Exonic is an AI-powered platform dedicated to advancing precision gene therapy. By utilizing artificial intelligence, Exonic aims to streamline and accelerate the drug discovery process, particularly in the realm of gene-based treatments. The tool is designed to assist researchers and companies within the biotechnology and pharmaceutical sectors in identifying, developing, and optimizing therapeutic interventions. Its core focus is on enhancing the precision and efficacy of gene therapies, ultimately contributing to faster development cycles and more targeted treatments for various conditions.

AIffinity offers an NMR-AI integrated drug discovery platform designed to accelerate hit discovery, lead optimization, and expand NMR structure determination. Their solutions include 4D-GraFID for protein structure determination up to 30 kDa, deepHitExplorer for AI-powered fragment screening using photo-CIDNP NMR, machine learning, and cheminformatics, and deepScaffOpt for lead optimization, combining ligand- and protein-observed NMR data with deep learning. AIffinity also provides biomolecular simulation consulting services through HT-REX, offering advanced molecular simulation workflows and rigorous statistical modeling. The platform aims to make previously 'undruggable' targets accessible.

Molecule AI leverages generative AI and advanced deep learning models to significantly speed up drug discovery. Their proprietary platform, MoleculeGEN, is an integrated solution for de novo drug design, enabling the creation of novel molecular structures tailored to specific characteristics without relying on existing compounds. It also provides robust lead optimization tools, allowing users to predict ADMET and drug-likeness properties, perform docking analysis, and accelerate QSAR generation. The platform is supported by a multidisciplinary team of AI experts, computational chemists, and medicinal chemists, ensuring a comprehensive approach to biomedical challenges. Molecule AI focuses on developing novel architectures built on biophysics principles to provide end-to-end solutions in drug design.

BioMap is an AI company dedicated to advancing life sciences through the generation of novel proteins for therapeutic and industrial applications. The company leverages cutting-edge artificial intelligence to build sophisticated foundation models, powered by extensive computational resources and proprietary biological data. BioMap partners with pharmaceutical and biotechnology companies, offering flexible collaboration models to accelerate their discovery ambitions. By applying its AI technology platform, BioMap aims to enable breakthroughs in drug discovery and development, providing innovative solutions for complex biological challenges. The focus is on creating a new paradigm for protein design and engineering, moving beyond traditional methods to unlock new possibilities in medicine and industry.

Ephion Health is a digital health platform that integrates data from wearables, clinical reports, and Artificial Intelligence to provide precise and sensitive patient assessment. It measures functional capacity through an easy-to-use, hardware-agnostic platform, offering user-tailored apps and customizable data sources. The system captures biomechanical and physiological data, clinical reports, and patient-reported outcomes, analyzing them with AI algorithms to return a composite score of patient functional capacity. This enables objective insights for enhanced care, efficient patient record management, and robust digital endpoints for clinical trials, addressing challenges in current assessment methods for various conditions like neuromuscular diseases and frailty.

AiCure offers H.Code, the world's first AI-powered adherence verification platform trusted by pharmaceutical companies, CROs, and healthcare providers. This platform utilizes AI-powered computer vision, synchronous chat, and predictive analytics to observe and assist trial participants via their smartphones. H.Code revolutionizes access and participation in clinical trials, improving statistical power and deepening the understanding of the relationship between patient behavior and trial outcomes. It supports various study models, including traditional site-based, decentralized, fully virtual, or hybrid, and helps reduce early termination rates by predicting retention risks.

Argon AI is an AI-powered platform designed for the Pharma, Biotech, and Life Sciences sectors, offering insights and automation to streamline workflows. The tool provides a unified knowledge base, granting access to a comprehensive collection of secondary data including medical literature, company information, and preclinical to commercial assets. It also integrates proprietary Sell-side Analyst Research from over 50 leading healthcare banks. Argon AI aims to significantly reduce the time and cost associated with bringing life-changing therapies to market, which currently can take 15 years and cost over $2 billion. It supports clinical and commercial teams by automating data-intensive tasks, generating insights, and improving efficiency in research and development.

ArtificaX Technologies is a deep-tech company that translates frontier research into practical products, focusing on AI agents and drug discovery. Their flagship product, RapidDrug, offers AI-powered, end-to-end, billion-ligand-scale in-silico drug discovery, claiming to be up to 1000 times faster at a fraction of the cost. Additionally, they offer AXAgents, AI agents powered by large language models capable of booking reservations, making purchases, and performing planning tasks over the Internet through API integration. ArtificaX aims to bridge the gap between fundamental research and commercial products, providing platforms that foster innovation in both drug discovery and AI.

PharosBio is an AI-powered decision-support framework designed to accelerate scientific decisions in life sciences. It unifies experimental data, publications, and internal documents, transforming them into fast, reliable, and fully traceable actionable insights. The platform addresses challenges in drug development such as data silos and incomplete pipeline oversight by connecting insights from early discovery, through preclinical stages, to clinical outcomes. It supports hypothesis generation, target selection, and prioritization, and helps predict translatability of in vivo results. PharosBio emphasizes enterprise security and compliance, adhering to industry best practices for data protection, encryption, role-based access controls, and supporting certifications like GDPR, SOC2, and HIPAA.

MedAware is an AI-powered medication safety monitoring platform designed to identify preventable medication-related risks throughout the patient journey. Utilizing advanced machine learning algorithms and outlier detection mechanisms, similar to those used in financial fraud detection, MedAware integrates seamlessly within existing health data systems and connected devices via vendor-agnostic APIs. This technology offers 24/7 monitoring to detect dangerous, undetected risks and liabilities, driving clinical relevance and accuracy for unprecedented behavior change. MedAware's proprietary methodology aims to improve financial, operational, and clinical outcomes, providing a crucial layer of protection that enhances patient safety and reduces medication errors.